

	All pts		Pts with PD-L1+ tumors	
	Avelumab + BSC (n=350)	BSC alone (n=350)	Avelumab + BSC (n=189)	BSC alone (n=169)
Median OS (95% CI), months	23.8 (19.9-28.8)	15.0 (13.5-18.2)	30.9 (24.0-39.8)	18.5 (14.1-24.2)
HR for OS (95% CI); 2-sided p value	0.76 (0.631-0.915); p=0.0036		0.69 (0.521-0.901); p=0.0064	
30-month OS rate, % (95% CI)	43.7 (38.2-49.0)	33.5 (28.4-38.7)	51.3 (43.7-58.4)	38.5 (30.9-46.1)
Restricted mean survival time (95% CI), months; 2-sided p value	28.8 (26.6-31.0); p=0.0029	24.1 (21.9-26.3)	32.4 (29.4-35.4) p=0.0080	26.4 (23.2-29.7)
Median PFS by investigator (95% CI), months	5.5 (4.2-7.2)	2.1 (1.9-3.0)	7.5 (5.5-11.1)	2.8 (2.0-3.7)
HR for PFS (95% CI); 2-sided p value	0.54 (0.457-0.645); p< 0.0001		0.46 (0.360-0.588); p< 0.0001	
30-month PFS rate, % (95% CI)	19.3 (15.0-24.0)	6.3 (3.8-9.5)	25.1 (18.6-32.2)	6.7 (3.3-11.6)